Menopause-related osteoporosis

Leon Snyman

Department of Obstetrics and Gynaecology, University of Pretoria, Pretoria

Author e-mail: leon.snyman@up.ac.za

Peak bone mass for spine and hip is reached in the mid-twenties and adolescents should be counselled on adequate nutrition to ensure sufficient calcium intake, regular weight-bearing exercise, maintaining normal body weight, avoiding smoking and limiting alcohol intake. These measures are important to prevent osteopenia and osteoporosis by obtaining a maximum peak bone mineral density (BMD) and to maintain it by avoiding excessive bone loss. One year before the onset of menopause, however, as a result of oestrogen deficiency, there is an increase in osteoclastic activity without a similar increase in osteoblastic activity, resulting in accelerated bone loss. The average decrease in BMD during the menopausal transition is estimated to be about 10% and a woman’s risk of sustaining an osteoporotic or fragility fracture doubles for each decade after the age of fifty. Half of women older than 50 years of age will be osteopenic compared to 10% who are osteoporotic and only 40% will have normal BMD. This article gives an overview of the prevention, diagnosis and management of osteoporosis during and before menopause.

Keywords: fragility fractures, menopause, osteoporosis

Introduction

A higher percentage of women is living longer in certain communities. In the UK, it is estimated that 13% of women born in 1951 will be alive in 2051, and an estimated 40% of girls born in 2013 will celebrate their 100th birthday. This increase in life expectancy has also been reported in other countries, and should result in many women living through the postmenopausal stage of their lives for a further 50 years. Consequently, menopause-related osteoporosis will be a major health concern for these women and their healthcare providers.

Low bone mineral density (BMD) is responsible for a growing global health burden. Increased rates of age-standardised disability adjusted life years attributable to low body mass index have been observed in developing regions, such as sub-Saharan, East and West Africa. A woman’s risk of sustaining an osteoporotic or fragility fracture increases with age, and the risk doubles for each decade after the age of 50. There are serious implications following hip and vertebral fractures in older women. Fragility fractures result in pain, hospitalisation, loss of function and independence. More than half of women who have sustained hip fractures are unable to climb stairs, get in and out of the shower, or use a toilet without assistance one year after surgery. Mortality attributable to surgery following hip fractures is estimated to be approximately 4%, and roughly 20% of these patients will die within a year of sustaining a hip fracture.

Pathophysiology and diagnosis

Peak bone mass for the spine and hip is reached in the mid-20s. One year before the onset of menopause, there is an increase in osteoclastic activity without a similar increase in osteoblastic activity, resulting in accelerated bone loss as a result of oestrogen deficiency. The average decrease in BMD during the menopausal transition is estimated to be about 10%. In addition to BMD, bone quality also contributes to bone strength.

Risk factors for developing osteoporosis include age, gender, race, genetics and dietary calcium intake. Lifestyle issues, such as smoking, exercise, alcohol consumption and sunlight exposure, also contribute to this risk.

Osteoporosis is diagnosed in menopausal women when the BMD assessment by dual-energy X ray absorptiometry is less than or equal to 2.5 standard deviations below that of the young adult reference population. This value is known as the T-score. According to the World Health Organization (WHO) diagnostic guidelines, a T-score of +2.5 to −1 is normal, a T-score between −1.0 and −2.5 is osteopenia, and if the T-score is lower than −2.5, the individual is diagnosed as having osteoporosis.

Osteoporosis is diagnosed clinically in the presence of a fragility fracture regardless of the T-score. A fragility fracture is defined as a fracture resulting from a low trauma event, such as falling from a standing height or less.

The abovementioned diagnostic criteria are not applicable to healthy premenopausal women. The Z-score compares an individual’s BMD to that of an age-matched population, and this score is used in the diagnosis of osteoporosis in this group of women. A Z-score of more than 2 below the standard deviation of the mean should prompt investigations to diagnose underlying causes of bone loss.

A thorough history and physical examination is imperative to rule out secondary causes of osteoporosis in postmenopausal women. Special investigations that can be performed include full blood count, sedimentation rate, C-reactive protein level, serum calcium, albumin, creatinine, phosphate, alkaline phosphatase, liver transaminases and thyroid function tests. Further appropriate special investigations are indicated depending on the information obtained from the history and an examination, where possible, if secondary osteoporosis is suspected. If a secondary cause is not suspected, it is probably not necessary to perform additional special investigations. Table I provides a list of conditions that can cause secondary osteoporosis.

More elderly women with osteopenia will sustain fragility fractures than women with osteoporosis because of a higher...
Preventive pharmacological intervention, aimed at minimising bone loss and preventing fractures, should be individualised after clinical information, possible benefits, and the costs and risks attributable to different medications have been taken into consideration.

**Screening**

There are no universally accepted screening practices for osteoporosis due to unresolved issues with regard to cost and effectiveness of screening. Screening involves identifying patients at risk of sustaining fragility fractures, emphasising the importance of taking a complete and thorough history aimed at identifying these risk factors. Besides BMD, a history of a previous fragility fracture and advanced age are the most robust risk factors predicting fragility fracture risk.

The recommendations from different expert groups vary considerably. The United States Preventive Services Task Force (USPSTF) recommends BMD assessment in all post-menopausal women older than 65 years, and in younger women with one or more risk factors and a history of a previous fragility fracture. The National Osteoporosis Foundation (NOF) recommends BMD assessment in women between 50 and 70 years with risk factors. In the absence of formal recommendations, screening should be individualised and offered to post-menopausal and other women at risk for sustaining fragility fractures.

**Management**

Management of women with low and moderate fracture risk mainly centres on prevention. These women should be counselled with regard to healthy lifestyle measures and adequate dietary calcium and vitamin D intake. Besides a diet that ensures adequate calcium, vitamin D and protein intake, other nonpharmacological interventions include regular weight-bearing exercise and exercises aimed at strengthening muscles to reduce the risk of falls. Additional fall-prevention strategies, such as home safety assessment and modification interventions, replacing multifocal with single lenses, as well as a prescribing modification programme from primary care physicians, have been shown to significantly reduce the risk of falls in elderly community-dwelling individuals.

In addition to the above, pharmacological treatment should be considered in women with a high fracture risk. Women with T-scores below −2.5, and those with previous osteoporotic fractures are at high risk of osteoporotic fractures and might benefit from pharmacological intervention. The latter might be indicated in osteopenic women with a 10-year probability risk of hip fracture of 3% or more or a 20% probability risk of sustaining a major osteoporotic fracture.

**Available preparations**

**Hormone therapy**

Menopausal hormone therapy (MHT) in the form of oestrogen, with or without progesterin, is very effective in increasing

---

**Table I: Causes of secondary osteoporosis**

<table>
<thead>
<tr>
<th>Medical conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eating disorders</td>
</tr>
<tr>
<td>Gastrointestinal malabsorption</td>
</tr>
<tr>
<td>Vitamin D and/or calcium deficiency</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
</tr>
<tr>
<td>Hyperparathyroidism</td>
</tr>
<tr>
<td>Cushing’s syndrome</td>
</tr>
<tr>
<td>Hypogonadism</td>
</tr>
<tr>
<td>Chronic inflammatory conditions</td>
</tr>
<tr>
<td>Alcoholism</td>
</tr>
<tr>
<td>Renal disease</td>
</tr>
<tr>
<td>Liver disease</td>
</tr>
<tr>
<td>Osteogenesis imperfecta</td>
</tr>
<tr>
<td>Marfan’s syndrome</td>
</tr>
<tr>
<td>Hereditary haemochromatosis</td>
</tr>
<tr>
<td>Thalassemia major</td>
</tr>
<tr>
<td>Gaucher’s disease</td>
</tr>
<tr>
<td>HIV infection and/or medications</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>Thalassemia major</td>
</tr>
</tbody>
</table>

**Medications**

- Glucocorticoids
- Immunosuppressant drugs
- Antiepileptic drugs (phenobarbital and phenytoin)
- GnRH agonists
- Heparin
- Chemotherapy, causing amenorrhea
- Depot medroxyprogesterone acetate

GnRH: gonadotrophin-releasing hormone
HIV: human immunodeficiency virus

---

Number of women in the osteopenia group. Half of women older than 50 years will be osteopenic compared to 10% who are osteoporotic and 40% who have normal BMD. Women with osteopenia need to be assessed and managed for fracture risk using modalities such as the Fracture Risk Assessment Tool (FRAX®) which was developed by the WHO. Use of the FRAX® assessment tool is hampered by the limited availability of epidemiological fracture data from South Africa.
BMD, and more importantly, in reducing clinical fracture risk. Oestrogen decreases hip and other fractures by 30–50%.4 Hormone therapy should be the treatment of choice in women with osteoporosis aged 40–50 years, who do not have contraindications, and especially in women with menopausal symptoms. Hormonal treatment should not be initiated after the age of 60 years. Continued use after this age must be individualised. Extending MHT to individual women is acceptable practice when the benefits outweigh potential risks. Hormone therapy should be prescribed at a dose known to provide fracture risk reduction, which is 0.625 mg/day of conjugated equine oestrogen, or equivalent doses of other preparations.15

The protective effect on BMD and fracture risk is lost within two years of the cessation of hormone therapy. Therefore, it is important to reassess BMD and fracture risk in women who stop hormone therapy and to consider other treatment options when indicated.14

**Bisphosphonates**

Bisphosphonates act on an enzymatic level, reducing osteoclastic activity in bone, which results in the suppression of bone turnover and preservation of the bone architecture. Preparations include alendronate (Fosamax®), ibandronate (Bondronat®), risedronate (Actonel®) and zoledronic acid (Aclasta®). Alendronate combined with cholecalciferol (Fosavance®) can be administered weekly. Bisphosphonates are frequently used as first-line pharmacological treatment for menopause-related osteoporosis.

These preparations are effective in reducing fracture risk. Alendronate is associated with a relative risk reduction of 47% for vertebral fractures and 51% for hip fractures. The respective figures for risedronate are 41% and 30%, while 5 mg of zoledronic acid, infused yearly for three years, reduces vertebral fractures by 70% and hip fractures by 41%.

Oral bisphosphonates are poorly absorbed and must be taken on an empty stomach. Patients should not lie down for at least 30 minutes after ingestion. Oesophageal irritation is a common side-effect. Osteonecrosis of the jaw and atypical fractures are rare complications of bisphosphonate use in women treated for osteoporosis.13

Bisphosphonate treatment should be discontinued after 5–10 years, depending on the original clinical state and response to treatment. After the cessation of bisphosphonate therapy, BMD measurements, with or without bone turnover markers, should be performed every two years. Therapy can be recommenced if there is a consistent decrease in BMD.

**Selective oestrogen-receptor modulators**

Raloxifene (Evista®) acts like an oestrogen agonist in bone tissue, and as an antagonist on endometrial and breast tissue. It reduces vertebral fractures by 30%, and increases BMD significantly in the vertebra and the hip, but does not reduce the risk of non-vertebral fractures. It is contraindicated in women with previous venous thromboembolism (VTE), and does not relieve menopausal vasomotor symptoms.15,16

**Teriparatide**

This preparation contains recombinant human parathyroid hormone. It stimulates bone formation and the remodelling of bone, resulting in an increase in BMD and an improvement in bone architecture. It significantly increases BMD, and reduces vertebral fractures by 65% and non-vertebral fractures by 53%. BMD decreases rapidly after the cessation of therapy.17

Side-effects include hypercalcaemia, hypercalciuria, nausea and headaches. Teriparatide is indicated in cases of failed antiresorptive therapy, severe fracturing disease and osteoporosis secondary to glucocorticoid use. Treatment duration should not exceed 18 months.15

**Strontium ranelate**

Strontium ranelate inhibits bone resorption and increases bone formation. The reduction in vertebral fractures is 37% after 2 g/day over three years, and for the same dosage over the same time, 14% for non-vertebral fractures. Side-effects include diarrhoea, as well as potential vascular and nervous system side-effects.18 It should not be used in patients with peripheral vascular or cardiovascular disease, uncontrolled hypertension or women at risk of VTE.13

**Monitoring therapy**

There is no consensus as to what constitutes the optimal monitoring of patients being treated for menopause-related osteoporosis. The main reason for monitoring these patients is to identify patients who require a change in therapy.

Patients on treatment should be monitored clinically to exclude serious side-effects from drug treatment and the presence of new fractures.

Most guidelines recommend repeated BMD examinations to be performed every 1–2 years. An increase in BMD is associated with decreased fracture risk. Fracture risk is also decreased if the BMD remains stable.19 BMD changes of less than 2–3% in the spine and 5–6% at the hip may be as a result of precision error. There is inefficient evidence with regard to the choice of bone turnover markers to be used in routine clinical practice to monitor osteoporosis treatment response.20

**Conclusion**

Menopause-related osteoporosis remains an important women’s health issue, especially in healthy populations, and as an increasing number of women are living longer. Nonpharmacological interventions, such as adequate dietary calcium and vitamin D intake, smoking cessation, exercise and moderate alcohol consumption, are all effective in the prevention and treatment of osteoporosis.

MHT is still a safe and effective treatment option in women with osteoporosis and those with a high risk of fragility fracture. Bisphosphonates are a safe and effective first-line treatment option, and several other pharmacological interventions are available for poor responders or women with other clinical factors or contraindications.

**References**